Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: A 6-year pragmatic data review

Allergy and Asthma Proceedings

Volumn 33, Issue 2, 2012, Pages 172-177

  Storms, William ^a   Bowdish, Matthew S ^a   Farrar, Judith R ^b  

^a William Storms Allergy Clinic   (United States)

^b Life Sciences Press   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMALIZUMAB;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; ASTHMA; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; EMERGENCY CARE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; SCORING SYSTEM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CONTROLLED CLINICAL TRIALS AS TOPIC; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84860247083     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3527     Document Type: Article

References (20)

1. Genentech USA, Inc., and Novartis Pharmaceutical Corp. Xolair (omalizumab) prescribing information. Genentech USA, Inc., South San Francisco, CA, and Novartis Pharmaceutical Corp., East Hanover, NJ; 7/2010.
2. Holgate S, Buhl R, Bousquet J, et al. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Respir Med 103:1098-1113, 2009.
3. Rodrigo GJ, Neffen H, and Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for adults and children with asthma: A systematic review. Chest 139:28-35, 2011.
4. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60:309-316, 2005. (Pubitemid 40293346)
5. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18:254-261, 2001. (Pubitemid 32776398)
6. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108: 184-190, 2001. (Pubitemid 32735398)
7. Buhl R, Soler M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 20:73-78, 2002. (Pubitemid 34822924)
8. Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 91:154-159, 2003. (Pubitemid 36999474)
9. Niven R, Chunk KF, Panahloo Z, et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label study. Respir Med 102:1371-1378, 2008.
10. Holgate ST, Chuchalin AG, Herbert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab in severe allergic asthma. Clin Exp Allergy 34:632-638, 2004. (Pubitemid 38534897)
11. Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 59:701-708, 2004. (Pubitemid 38850344)
12. Ware JH, and Hamel MB. Pragmatic trials-Guides to better patient care? N Engl J Med 364:1685-1687, 2011.
13. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program, Expert Panel Report 3. National Heart, Lung, and Blood Institute, Washington, D.C., 2007. Available online at www.nhlbi.nih.gov/guidelines/asthma/asthgdln. pdf; accessed August 6, 2011.
14. Broder MS, Chang EY, Kamath T, and Sapra S. Poor disease control among insured users of high-dose combination therapy for asthma. Allergy Asthma Proc 31:60-67, 2010.
15. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody, rhuMAb-E25 Study Group. N Engl J Med 341:1966-1973, 1999. (Pubitemid 30010404)
16. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab on anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60:302-308, 2005. (Pubitemid 40293345)
17. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 101:1483-1492, 2007. (Pubitemid 46850589)
18. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy. Ann Intern Med 154:573-582, 2011.
19. Patil SU, and Long AA. The usefulness of biomarkers of airway inflammation in managing asthma. Allergy Asthma Proc 31:259-268, 2010.
20. Long AA, Fish JE, Rahmaoui A, et al. Baseline characteristics of patients enrolled in EXCELS: A cohort study. Ann Allergy Asthma Immunol 103:212-219, 2009.